ALS Centre – Vanvitelli, First Division of Neurology

Università degli Studi della Campania Luigi Vanvitelli

This “ALS Centre” is one of the most endorsed centers in Southern Italy, involved in several major national and international clinical trials on ALS. The research activity is also focused on neuroimaging and laboratory disease/outcome biomarkers, and neuropsychological issues in ALS and other motor neuron diseases.

Centro SLA Vanvitelli - LOGO
Università degli Studi della Campania Luigi Vanvitelli

The ALS Centre, belonging to the First Division of Neurology, University Hospital “Università degli Studi della Campania Luigi Vanvitelli” in Naples (Italy) is one of the most endorsed ALS centers in Southern Italy, involved in several major national and international clinical trials on ALS (such as, recently: TUDCA-ALS; RNS60-ALS; Co-ALS). We see approximately 80 new patients every year, and care for about 250 patients in a year. Our research activity is performed at the MRI Research Centre of the University of Campania Luigi Vanvitelli. This centre of excellence is based on a collaborative and multi-investigator neuroimaging research environment (including neurologists, neuropsychologists, bioinformaticians, and bioengineers) and focused on medical applications of advanced functional and structural magnetic resonance imaging techniques to study the brain. Moreover, our ALS centre is involved in 3 main clinical/research networks: European Reference Network for rare disease (ERN) –  Neuromuscular Diseases (Euro-NMD); ITALSGEN (ITalian Consortium for ALS GENetics); and NiSALS (Neuroimaging Society in ALS) Consortia.

Contact
Location
Piazza Luigi Miraglia, 2, 80138 Naples, Napels, Italië

Our Specialists

Gioacchino Tedeschi

Full Professor of Neurology, Chief of the First Division of Neurology

Prof. Gioacchino Tedeschi is Full Professor of Neurology and Chief of the […]

Gioacchino Tedeschi
Current trials
Recruiting
Phase iii

ATLAS trial

Industry trial
Biogen is conducting a clinical trial to evaluate the efficacy and safety and of an investigational drug for adults who do not have any clinical signs or symptoms of Amyotrophic Lateral Sclerosis (ALS) (that definitely indicate the onset of ALS) but do carry a certain superoxide dismutase 1 (SOD1) gene variant.
Read more
Recruiting
Phase iii

FUSION trial

Industry trial
In this study we investigate the safety and efficacy of the study drug ‘ION363’ for the treatment of ALS caused by mutations in the FUS gene. About 1% to 5% of ALS cases are caused by FUS mutations.
Read more
Active
Phase iii

PHOENIX trial

Industry trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035' for the treatment of ALS.
Read more
Active
Phase iii

ADORE trial

Industry trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
Read more
Active
Phase iii

TUDCA-ALS

Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.
Read more